Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06092684
Other study ID # BT-KTM-I-III-01
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date October 2023
Est. completion date April 2024

Study information

Verified date October 2023
Source Chengdu Brilliant Pharmaceutical Co., Ltd.
Contact Wen Ouyang, MD
Phone 0731-88618151
Email Ouyangwen133@vip.sina.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective is to evaluate the efficacy and safety of BT-KTM-I(Esketamine Hydrochloride Injection produced by Chengdu Brilliant Pharmaceutical Co., Ltd.) for general anesthesia, using the Originator drug Ketanest®S(Esketamine Hydrochloride Injection) as a positive control.


Description:

This is a multicenter, randomized, double-blind, positive drug parallel controlled clinical trial, planned to include 358 subjects, including 179 in the experimental group and 179 in the control group. The entire study was divided into a screening period, surgery day, and follow-up observation period. The dosage for anesthesia induction period was 0.5mg/kg, and the dosage for anesthesia maintenance period was 0.5mg/kg/h. The experiment used vital signs, physical examination, laboratory examination, 12-lead electrocardiogram examination, and adverse events/serious adverse events for safety evaluation.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 358
Est. completion date April 2024
Est. primary completion date January 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: 1. Age range from 18 to 60 years old (including threshold), regardless of gender; 2. Patients undergoing elective general anesthesia laparoscopic surgery (only tracheal intubation mechanical ventilation), 1 hour = expected anesthesia time = 2.5 hours; 3. The American Society of Anesthesiologists (ASA) score of Class I or II; 4. 18kg/m2<BMI<30kg/m2; 5. The subjects understand the purpose and procedure of this experiment, voluntarily participate in this experiment, and sign a written informed consent form. Exclusion Criteria: 1. Patients with contraindications to general anesthesia, or those who have had previous anesthesia accidents; 2. Known intolerance or allergy to ketamine hydrochloride, esketamine hydrochloride, propofol, rocuronium bromide, opioids, neostigmine, atropine, belladonnae alkaloids; 3. Long-term (continuous or intermittent) use of benzodiazepines sleeping pills, opioid analgesics, or use of narcotic analgesics within 24 hours before randomization or use of narcotic drugs within 7 days; 4. Have a history of increased intraocular pressure (such as glaucoma) or puncture eye injury; 5. Patients with a history of asthma; 6. Patients with mental system diseases (schizophrenia, mania, insanity, etc.) or cognitive disorders; 7. Patients with a history of craniocerebral injury, possible presence of intracranial hypertension, cerebral aneurysm, cerebrovascular accident, and central nervous system disease; 8. Have a serious history of cardiovascular diseases (such as myocardial ischemia, heart failure and severe arrhythmia); Angina pectoris (unstable angina) caused by insufficient blood supply to the coronary arteries of the heart, or myocardial infarction occurring within the first 6 months before screening; 9. Hypertensive patients with systolic blood pressure still = 140mmHg and/or diastolic blood pressure still = 90mmHg after treatment with antihypertensive drugs; 10. Diabetic patients whose blood glucose was not satisfactorily controlled (fasting blood glucose =11.1mmol/L during the screening period); 11. Severe lipid metabolism abnormalities (such as triglycerides>5mmol/L, diabetic hyperlipidemia, familial hypercholesterolemia, lipoid nephropathy, acute pancreatitis with hyperlipidemia, etc.); 12. Have a history of hyperthyroidism; 13. Have a history of drug use within 2 years before screening; 14. Individuals with a history of alcohol abuse within 2 years before screening. alcoholism is defined as drinking more than 14 units of alcohol per week (1 unit =360mL beer or 45mL spirits with 40% alcohol or 150mL wine) or acute alcoholism or alcohol dependence; 15. Participants in any clinical trial (defined as receiving the experimental drug or placebo) within 3 months prior to screening; 16. Patients with respiratory management difficulties as determined by the investigators (modified Markov score level ?); 17. Abnormal coagulation function (PT or PT-INR = 1.5×ULN, APTT = 1.5×ULN), or with bleeding tendency (such as active digestive ulcer) or undergoing thrombolytic or anticoagulant treatment; 18. Anemia or thrombocytopenia (PLT=80×109/L, HGB=90g/L); 19. Abnormal liver function [ALT and (or) AST=1.5×ULN, TBIL=1.5×ULN]; 20. Abnormal renal function (BUN=1.5×ULN; Cr=1.2×ULN) 21. Pregnant or lactating women; Women or men with fertility are unwilling to use contraception between the screening period and the end of the trial; 22. Subjects who are deemed by the investigators to have any other unfavorable factors for participating in this clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
BT-KTM-I
The dosage for anesthesia induction period was 0.5mg/kg, and the dosage for anesthesia maintenance period was 0.5mg/kg/h.
Ketanest®S
The dosage for anesthesia induction period was 0.5mg/kg, and the dosage for anesthesia maintenance period was 0.5mg/kg/h.

Locations

Country Name City State
China Hunan Provincial Maternal and Child Health Care Hospital Changsha Hunan
China The Third Xiangya Hospital of Central South University Changsha Hunan
China Pidu District People's Hospital, Chengdu Chengdu Sichuan
China Sichuan Provincial People's Hospital Chengdu Sichuan
China West China Second University Hospital, Sichuan University Chengdu Sichuan
China The First Affiliated Hospital of Jinan University Guangzhou Guangdong
China The First Affiliated Hospital, Sun Yat-sen University Guangzhou Guangdong
China Guizhou Provincial People's Hospital Guiyang Guizhou
China The Affiliated Hospital of Guizhou Medical University Guiyang Guizhou
China The Second Hospital University of South China Hengyang Hunan
China The Second People's hospital of Neijiang Neijiang Sichuan
China The Second People's Hospital of Yibin Yibin Sichuan

Sponsors (1)

Lead Sponsor Collaborator
Chengdu Brilliant Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The awakening time from anesthesia The time from discontinuing the use of anesthetics (propofol) to subjects waking up immediately after surgery (following instructions to open their eyes)
Secondary Incidence of adverse reactions in the mental system Within 60 minutes after the subject wakes up
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04515485 - A Volumetric Nomogram for Height, Weight, and Intra Abdominal Volume
Completed NCT01725477 - Laparoscopic Tubal Patency Assessment N/A
Recruiting NCT01093430 - Is the Anterior Superior Iliac Spine a Useful Landmark at Laparoscopy? N/A
Recruiting NCT01093079 - Laparoscopic Versus Open Partial Nephrectomy - Surgical and Oncological Outcomes N/A
Completed NCT00535990 - Minimally Invasive Surgery (MIS) Database for the Purpose of Research
Completed NCT01092013 - Comparative Evaluation of Simulator Based and Traditional In-surgery Laparoscopic Camera Training's Efficiency in Novices N/A
Recruiting NCT06044909 - Multimodal Image Registration for Helping Laparoscopic Liver Surgery Guidance
Not yet recruiting NCT05389241 - Laparoscopic Augmented Reality for Identification of Liver Lesions - a Pre-clinical Randomized Cross-over Trial N/A
Completed NCT06255080 - Comparing Skills Acquisition on Different Laparoscopy Software N/A
Enrolling by invitation NCT03234543 - Remote Ischemic Conditioning in Abdominal Surgery N/A
Recruiting NCT02827292 - Effect of Music on Inflammatory Response During Laparoscopic Surgery N/A
Terminated NCT01008709 - Comparison Study of Two Different Surgical Clips During Laparoscopic Urologic Surgery N/A
Active, not recruiting NCT05363813 - Post-market Clinical Follow-up Study of Reusable Clip Applier Cartridge Devices for LAParoscopic Surgery N/A
Completed NCT03330236 - EEG - Guided Anesthetic Care and Postoperative Delirium N/A
Recruiting NCT05031182 - Tolerance of the vNOTES Surgical Technique in Total Hysterectomy for Benign Lesion. Clinical Trial of Non-inferiority Compared to the Laparoscopic Technique. N/A
Active, not recruiting NCT05302622 - Detecting the Most Efficient Residency Time for Laparoscopic Simulators N/A
Recruiting NCT03684291 - Hemodynamic Effects of Ventilation Modes
Recruiting NCT06117748 - Volume-Controlled Ventilation and Pressure-Controlled Ventilation Volume Guaranteed in Obese Patients in Laparoscopic-Assisted Surgery N/A
Recruiting NCT03739944 - Different Surgical Approaches in Patients of Early-stage Cervical Cancer Phase 3
Completed NCT02079337 - Validation of Subjective Rating Scales Used to Assess Surgical Conditions in Abdominal Surgery Phase 4